Targeting oncogenic Myc as a strategy for cancer treatment

H Chen, H Liu, G Qing - Signal transduction and targeted therapy, 2018 - nature.com
The MYC family oncogene is deregulated in> 50% of human cancers, and this deregulation
is frequently associated with poor prognosis and unfavorable patient survival. Myc has a …

Targeting PI3K/Akt/mTOR signaling in cancer

C Porta, C Paglino, A Mosca - Frontiers in oncology, 2014 - frontiersin.org
The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin
(mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and …

PI3K and cancer: lessons, challenges and opportunities

DA Fruman, C Rommel - Nature reviews Drug discovery, 2014 - nature.com
The central role of phosphoinositide 3-kinase (PI3K) activation in tumour cell biology has
prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and …

The Akt pathway in oncology therapy and beyond

GM Nitulescu, M Van De Venter… - International …, 2018 - spandidos-publications.com
Protein kinase B (Akt), similar to many other protein kinases, is at the crossroads of cell
death and survival, playing a pivotal role in multiple interconnected cell signaling …

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

J Polivka Jr, F Janku - Pharmacology & therapeutics, 2014 - Elsevier
Aberrations in various cellular signaling pathways are instrumental in regulating cellular
metabolism, tumor development, growth, proliferation, metastasis and cytoskeletal …

[HTML][HTML] Akt, FoxO and regulation of apoptosis

X Zhang, N Tang, TJ Hadden, AK Rishi - Biochimica et Biophysica Acta …, 2011 - Elsevier
Forkhead box O (FoxO) transcription factors are downstream targets of the serine/threonine
protein kinase B (PKB)/Akt. The Akt kinase regulates processes of cellular proliferation and …

AKT in cancer: new molecular insights and advances in drug development

PS Mundi, J Sachdev, C McCourt… - British journal of clinical …, 2016 - Wiley Online Library
The phosphatidylinositol‐3 kinase (PI3K)–AKT pathway is one of the most commonly
dysregulated pathways in all of cancer, with somatic mutations, copy number alterations …

PTEN loss in the continuum of common cancers, rare syndromes and mouse models

MC Hollander, GM Blumenthal, PA Dennis - Nature Reviews Cancer, 2011 - nature.com
PTEN is among the most frequently inactivated tumour suppressor genes in sporadic
cancer. PTEN has dual protein and lipid phosphatase activity, and its tumour suppressor …

[HTML][HTML] Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

JA McCubrey, LS Steelman, WH Chappell… - Oncotarget, 2012 - ncbi.nlm.nih.gov
Abstract The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by
genetic alterations in upstream signaling molecules such as receptor tyrosine kinases …

Industrial natural product chemistry for drug discovery and development

A Bauer, M Brönstrup - Natural product reports, 2014 - pubs.rsc.org
Covering: up to March 2013 In addition to their prominent role in basic biological and
chemical research, natural products are a rich source of commercial products for the …